Glucose Fresenius

Glucose Fresenius is an intravenous solution for injection that contains the active ingredient glucose as its sole component. It is supplied in a sterile aqueous solution without a specified strength, and is classified as an excipient/solvent used in parenteral nutrition. The product is marketed in the European Union and requires a prescription. It provides a readily available carbohydrate source for patients needing intravenous energy support.

Glucose Fresenius is indicated for clinical situations where an intravenous carbohydrate source is required to maintain blood glucose levels and support nutritional needs, particularly when oral intake is limited or contraindicated. It is commonly incorporated into fluid therapy protocols and can be adjusted to meet individual caloric requirements. - Treatment of hypoglycemia when oral glucose is not feasible. - Component of total parenteral nutrition regimens. - Fluid and electrolyte replacement solutions. - Energy source during perioperative fasting. - Support for patients with impaired oral intake. - Used in pediatric and neonatal intensive care for glucose maintenance.

When administered intravenously, Glucose Fresenius may be associated with a range of adverse reactions that vary in frequency and severity. The frequency of these events depends on patient factors, infusion rate, and total carbohydrate load. Common: - Mild hyperglycemia or transient rise in blood glucose. - Local irritation at the infusion site. - Nausea or vomiting. - Electrolyte shifts such as mild hyponatremia. - Headache or dizziness during rapid infusion. - Mild metabolic acidosis in prolonged high‑dose therapy. Serious: - Severe hyperglycemia leading to osmotic diuresis. - Allergic reactions including rash, urticaria, or anaphylaxis. - Volume overload in patients with compromised cardiac function. - Hyperosmolar state with dehydration in patients receiving large volumes.

Glucose Fresenius should be used with attention to specific clinical considerations to minimize risks and ensure appropriate therapeutic outcomes. - Verify blood glucose levels before and during infusion. - Adjust infusion rate in patients with renal or hepatic impairment. - Monitor fluid balance to avoid volume overload. - Use caution in patients with diabetes mellitus or insulin resistance. - Assess electrolyte status, especially sodium and potassium, prior to administration. - Avoid rapid bolus administration unless clinically indicated, and monitor closely. - Consider compatibility with other intravenous solutions before mixing.

When co‑administered carefully with other agents, Glucose Fresenius may affect or be affected by concurrent medications, requiring attention to potential interactions. Avoid: - Do not mix with calcium-containing solutions without compatibility testing. - Avoid simultaneous infusion with high‑dose insulin without appropriate glucose monitoring. Use with caution: - Use cautiously with diuretics that may alter electrolyte balance. - Monitor closely when combined with beta‑blockers that can mask hypoglycemia symptoms. - Adjust dosage when given with glucocorticoids that increase glucose production. - Be vigilant when co‑administered with vasopressors that may affect peripheral perfusion. - Consider glucose monitoring when combined with oral hypoglycemic agents.